The role of myeloid cells in cancer therapies

By Camilla Engblom, C. Pfirschke, M. Pittet. Nature Reviews. Cancer, 2016

698 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Single cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species (2019, background): “Tumor-infiltrating neutrophils have been ascribed both anti- and pro-tumor properties, as well as diverse molecular phenotypes (Coffelt et al., 2016; Engblom et al., 2016).”
Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, positive): “High expression of CCL2 in tumors and high count of CCR2 monocytes in the peripheral blood are both correlated with poor prognosis in several cancer types [108][105][109].”
Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 (2018, neutral): “, 2014), as these cells are often abundant in tumors (Engblom et al., 2016).”
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control (2018, background): “In contrast, M1-polarized macrophages and DCs contribute to anti-tumor immunity and are associated with a favorable outcome (Engblom et al., 2016).”
Clinical relevance of tumour-associated macrophages (2022, background): “Several aspects currently being addressed include: (1) the complexity and diversity of macrophages, and whether distinct macrophage states can be identified; (2) whether and how different macrophage states contribute to disease progression or suppression; (3) the possibility of rational manipulation”